BioNTech and its partner Pfizer have terminated a U.S. study for their updated COVID-19 vaccine. The decision was not prompted by safety concerns but by a significant lack of participant enrollment, highlighting the diminished public focus on the pandemic.
Strategic Pivot Gains Momentum
This development aligns with BioNTech’s broader strategic roadmap. The company’s revenue forecast for 2026 is set between €2.0 billion and €2.3 billion, a decline from the €2.9 billion projected for 2025. This expected drop is a direct reflection of waning global demand for coronavirus vaccines.
The halted trial was designed for healthy adults aged 50 to 64, aiming to gather post-marketing data on the latest vaccine formulations. Initial plans targeted 25,000 to 30,000 participants. However, recruitment was officially closed on March 6 due to insufficient interest. According to a Pfizer communication to trial investigators dated March 30, active participant monitoring will cease on April 3. Both companies explicitly stated that the vaccine’s safety profile remains unchallenged; the data from the limited enrollment would simply have been statistically inconclusive.
Should investors sell immediately? Or is it worth buying BioNTech?
Oncology Pipeline Fuels Future Growth
Concurrently, BioNTech is channeling substantial resources into its oncology research. Adjusted research and development expenses are projected to rise to between €2.2 billion and €2.5 billion in 2026. This ambitious investment is supported by a robust liquidity position, with the company holding €17.2 billion in cash and marketable securities at the end of 2025.
The oncology pipeline is set to expand significantly, with 15 ongoing Phase 3 trials anticipated by the end of 2026. Market analysts are particularly focused on upcoming data readouts. These include interim results for pumitamig in triple-negative breast cancer, gotistobart in lung squamous cell carcinoma, and Phase 2 data for T-Pam in endometrial cancer. The latter program is viewed as a potential catalyst for BioNTech’s first independent oncology product launch.
In early U.S. trading, the company’s shares saw a modest increase of approximately 0.5% following the news. The narrative is clearly evolving: as the chapter on COVID-19 vaccines draws to a natural close, BioNTech is authoring its next major story in cancer therapeutics.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from April 3 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 3.
BioNTech: Buy or sell? Read more here...
